利什曼病,利什曼原虫属。,和查加斯病,克氏锥虫生产的,影响全世界数百万人。这些病症的治疗并不完全有效,并且产生一些副作用。由于这些原因,有必要开发对患者更活跃,毒性更小的新疗法。一些倡议,例如由疟疾药品风险投资公司进行的一次,允许筛选大量不同来源的化合物,以找到缺乏锥虫杀菌剂治疗的替代品。在这项工作中,从全球卫生优先箱测试了240种化合物(80种化合物具有确认的抗抗药性疟疾活性,80种化合物用于筛选被忽视和人畜共患疾病以及有耐药性风险的疾病,和80种对各种载体物种具有活性的化合物)对克氏锥虫和亚马逊利什曼原虫。氟呋喃,一种具有抗载体活性和先前报道的抗葡萄球菌活性的化合物。和血吸虫。,证明了对亚马逊乳杆菌和克氏杆菌的活性,并在寄生虫中产生程序性细胞死亡。Flucofuron似乎是继续研究并证明其用作杀锥虫剂的良好候选者。
Leishmaniasis, produced by Leishmania spp., and Chagas disease, produced by Trypanosoma cruzi, affect millions of people around the world. The treatments for these pathologies are not entirely effective and produce some side effects. For these reasons, it is necessary to develop new therapies that are more active and less toxic for patients. Some initiatives, such as the one carried out by the Medicines for Malaria Venture, allow for the screening of a large number of compounds of different origins to find alternatives to the lack of trypanocide treatments. In this work, 240 compounds were tested from the Global Health Priority Box (80 compounds with confirmed activity against drug-resistant malaria, 80 compounds for screening against neglected and zoonotic diseases and diseases at risk of drug resistance, and 80 compounds with activity against various vector species) against Trypanosoma cruzi and Leishmania amazonensis.
Flucofuron, a compound with activity against vectors and with previous activity reported against Staphylococcus spp. and Schistosoma spp., demonstrates activity against L. amazonensis and T. cruzi and produces programmed cell death in the parasites.
Flucofuron seems to be a good candidate for continuing study and proving its use as a trypanocidal agent.